Biogen Idec has won European regulatory approval for a new delivery method for its blockbuster multiple sclerosis (MS) drug, Avonex, called the Avonex Pen. This is the first approval for the Avonex ...
European Commission approves the first single-use intramuscular autoinjector designed to improve convenience of once-weekly AVONEX (interferon beta-1a) administration “At Biogen Idec, our commitment ...
Study showed 94% of patients preferred new device over existing Avonex prefilled syringe. The European regulatory authorities approved Biogen Idec’s single-use intramuscular autoinjector, Avonex PEN, ...
-- First single-use intramuscular autoinjector designed to improve convenience of once-weekly AVONEX recommended for approval in the European Union and authorised in Canada -- AVONEX PEN is designed ...
AVONEX PEN (interferon beta-1a) 30mcg/0.5mL solution for injection by Biogen Idec Biogen Idec has received approval from the FDA for Avonex Pen (30mcg/0.5mL solution for injection) for patients ...
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Biogen Idec Canada Inc today announced AVONEX ® PEN ™ is now available for patients with relapsing multiple sclerosis (MS) and patients with a single ...
AVONEX PEN (interferon beta-1a) 30mcg/0.5mL solution for injection by Biogen Idec The Avonex Pen (interferon beta-1a 30mcg/0.5mL solution for injection), the first IM autoinjector for chronic use in ...
The U.S. Food and Drug Administration has approved a new prefilled syringe for Biogen's drug Avonex. Avonex, a once-a-week treatment for multiple sclerosis, is now approved in a prefilled syringe ...
-- First single-use intramuscular autoinjector designed to improve convenience of once-weekly AVONEX recommended for approval in the European Union and authorised in Canada -- AVONEX PEN is designed ...
ZUG, Switzerland--(BUSINESS WIRE)--Third paragraph, first sentence should read: ....AVONEX 30mcg/0.5ml... (sted ...AVONEX 30mcg/50ml...) The corrected release reads ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results